Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$39.01M+55.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Van Oene
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 485
- Beta
- 2.31
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.44
Financials
Revenue
$39.01M+55.3%Net Income
$-44.74MEBITDA
$-38.05MFree Cash Flow
$-84.87MEPS (diluted)
$-0.14Shares Outstanding (diluted)
310.65M+237.3%Operating Expenses
$56.41MCash & Debt
$236.87MRevenue by Segment (annual)
$295.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $160.00M | $-546.38M | $-1.82 |
| 2024 | $154.01M | $-309.85M | $-1.13 |
| 2023 | $200.52M | $-306.74M | $-1.21 |
| 2022 | $128.30M | $-314.25M | $-1.40 |
| 2021 | $130.51M | $-181.22M | $-0.89 |
| 2020 | $78.89M | $29.40M | $0.18 |
| 2019 | $90.89M | $-84.13M | $-0.51 |
| 2018 | $78.63M | $-102.56M | $-0.76 |
| 2017 | $93.47M | $-92.19M | $-0.87 |
| 2016 | $90.71M | $-74.38M | $-0.83 |
| 2015 | $92.78M | $-31.70M | $-0.42 |
| 2014 | $60.59M | $-66.16M | $-0.94 |
| 2013 | $28.18M | $-79.29M | $-1.26 |
| 2012 | $25.98M | $-94.47M | $-1.69 |
Valuation
PACBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (9)
- Newszacks.com·3d ago·Neutral
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
View source ↗ - Newszacks.com·10d ago·Positive
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
View source ↗ - Newszacks.com·18d ago·Neutral
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·25d ago·Neutral
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
View source ↗ - Newszacks.com·31d ago·Neutral
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue? Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·33d ago·Negative
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
View source ↗ - Newsmarketbeat.com·51d ago·Neutral
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.13 per share
Typical surprise +26.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.14 vs $-0.13miss
- Thu, May 7$-0.03 vs $-0.17beat
- Thu, Feb 12$-0.12 vs $-0.19beat
- Wed, Nov 5$-0.12 vs $-0.16beat
- Thu, Aug 7$-0.13 vs $-0.18beat
- Thu, May 8$-1.44 vs $-0.19miss
Estimates and results for PACB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PACB officers and directors.
- Bought
- $176k
- Sold
- $2.7m
1 trade
29 trades
- Van Oene Marksold
- Gibson James R Iisold
- Henry Christian Osold
- Van Oene Marksold
- Farmer Michelesold
- Van Oene Marksold
- Henry Christian Osold
- Farmer Michelesold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PACB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.